Carl Wijburg - Academia.edu (original) (raw)
Papers by Carl Wijburg
Scientific Reports
Robot-Assisted Radical Prostatectomy (RARP) is one of the standard treatment options for prostate... more Robot-Assisted Radical Prostatectomy (RARP) is one of the standard treatment options for prostate cancer. However, controversy still exists on its added value. Based on a recent large-sample retrospective cluster study from the Netherlands showing significantly improved long-term urinary functioning after RARP compared to Laparoscopic RP (LRP), we evaluated the cost-effectiveness of RARP compared to LRP. A decision tree was constructed to measure the costs and effects from a Dutch societal perspective over a ~ 7 year time-horizon. The input was based on the aforementioned study, including patient-reported consumption of addition care and consumed care for ergonomic issues reported by surgeons. Intervention costs were calculated using a bottom-up costing analysis in 5 hospitals. Finally, a probabilistic-, one-way sensitivity- and scenario analyses were performed to show possible decision uncertainty. The intervention costs were €9964 for RARP and €7253 for LRP. Total trajectory costs...
ESMO Open
BACKGROUND Guidelines recommend neoadjuvant chemotherapy (NAC) for the treatment of nonmetastatic... more BACKGROUND Guidelines recommend neoadjuvant chemotherapy (NAC) for the treatment of nonmetastatic muscle-invasive bladder cancer (MIBC). NAC is, however, underutilized in practice because of its associated limited overall survival (OS) benefit and significant treatment-related toxicity. We hypothesized that the absence of circulating tumour cells (CTCs) identifies MIBC patients with such a favourable prognosis that NAC may be withheld. PATIENTS AND METHODS The CirGuidance study was an open-label, multicentre trial that included patients with clinical stage T2-T4aN0-N1M0 MIBC, scheduled for radical cystectomy. CTC-negative patients (no CTCs detectable using the CELLSEARCH system) underwent radical surgery without NAC; CTC-positive patients (≥1 detectable CTCs) were advised to receive NAC, followed by radical surgery. The primary endpoint was the 2-year OS in the CTC-negative group with a prespecified criterion for trial success of ≥75% (95% confidence interval (CI) ±5%). RESULTS A total of 273 patients were enrolled. Median age was 69 years; median follow-up was 36 months. The primary endpoint of 2-year OS in the CTC-negative group was 69.5% (N = 203; 95% CI 62.6%-75.5%). Two-year OS was 58.2% in the CTC-positive group (N = 70; 95% CI 45.5%-68.9%). CTC-positive patients had a higher rate of cancer-related mortality [hazard ratio (HR) 1.61, 95% CI 1.05-2.45, P = 0.03] and disease relapse (HR 1.87, 95% CI 1.28-2.73, P = 0.001) than CTC-negative patients. Explorative analyses suggested that CTC-positive patients who had received NAC (n = 22) survived longer than CTC-positive patients who had not (n = 48). CONCLUSION The absence of CTCs in MIBC patients was associated with improved cancer-related mortality and a lower risk of disease relapse after cystectomy; however, their absence alone does not justify to withhold NAC. Exploratory analyses suggested that CTC-positive MIBC patients might derive more benefit from NAC. TRIAL REGISTRATION Netherlands Trial Register NL3954; https://www.trialregister.nl/trial/3954.
European Urology Supplements, 2018
Development and internal-external validation of a multivariable prediction model for pre-operativ... more Development and internal-external validation of a multivariable prediction model for pre-operative assessment of positive lymph nodes during robot assisted prostatectomy in two Dutch high volume robotic centers
The Journal of Urology, 2016
European Urology Supplements, 2012
European Urology Supplements, 2015
ABSTRACT Collins J.1, Hosseini A.1, Nyberg T.1, Schumacher M.C.2, Wijburg C.3, Canda A.E.4, Balba... more ABSTRACT Collins J.1, Hosseini A.1, Nyberg T.1, Schumacher M.C.2, Wijburg C.3, Canda A.E.4, Balbay M.D.5, Decaestecker K.6, Schwentner C.7, Edeling S.8, Pokupić S.8, Mottrie A.9, Guru K.10, Wiklund N.P.1 1Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden, 2Hirslanden Klinik, Dept. of Urology, Aarau, Switzerland, 3Rijnstate Hospital, Dept. of Urology, Arnhem, The Netherlands, 4Yildirim Beyazit University, Dept. of Urology, Ankara, Turkey, 5Memorial Hospital, Dept. of Urology, Istanbul, Turkey, 6Zekenhuis University, Dept. of Urology, Ghent, Belgium, 7Tubingen University Hospital, Dept. of Urology, Tubingen, Germany, 8Da Vinci Zentrum, Dept. of Urology, Hanover, Germany, 9OLV Clinic, Dept. of Urology, Aalst, Belgium, 10Roswell Park Cancer Institute, Dept. of Urology, Buffalo, United States of America INTRODUCTION & OBJECTIVES: Radical cystectomy is associated with high complications rates irrespective of surgical approach. Worldwide most centers offering robot-assisted radical cystectomy (RARC) perform an extracorporeal urinary diversion, despite potential advantages of a completely minimally invasive technique. We describe complication outcomes after totally intracorporeal RARC from a multi-institutional database using a standardized and validated reporting methodology. MATERIAL & METHODS: Using the ERUS Scientific Working Group (ESWG) database, we identified 428 patients who underwent totally intracorporeal RARC with at least 90 days of follow-up. Complications were analyzed and graded according to the Clavien-Dindo Classification system and were further stratified by organ system. Secondary outcomes included identification of preoperative and intraoperative variables associated with the complications. Logistic regression models were used to define predictors of complications and readmission, using backward selection (p<0.05). RESULTS: Overall 64% (n=274) of patients experienced a complication within 90 days of their operation, 57% (n=242) and 23% (n=96) within 30 days and 30-90 days of surgery respectively. 36% of patients experienced low grade complications (Clavien grade 1-2) and 29% experienced high grade complications (Clavien grade ≥3). Thirty and 90 day mortality was 0.9% and 2.1%, respectively. Overall 30 day readmission rate was 27%. Infectious, gastrointestinal and genitourinary complications were most common (40%, 26%, and 21%, respectively). On multi-variable analysis of 0-90 day complications we found neobladder diversion and increasing age to be predictors of any grade complications. As a multi-institutional database, disparities in patient selection, operating standards and postoperative management are potential limitations of this study. CONCLUSIONS: Surgical morbidity after totally intracorporeal RARC is significant when reported using standardized reporting methods. The majority of complications are low grade. Accurate reporting of complications is necessary to clarify optimum approaches to radical cystectomy and to guide patient counseling.
The Journal of Urology, 2015
ABSTRACT INTRODUCTION AND OBJECTIVES Data on the oncological outcomes in patients undergoing robo... more ABSTRACT INTRODUCTION AND OBJECTIVES Data on the oncological outcomes in patients undergoing robot-assisted radical cystectomy (RARC) is limited. Globally extracorporeal urinary diversion following RARC remains the most common approach despite potential advantages of a completely minimally invasive approach. We report oncological outcomes and associated prognostic factors from a multi-institutional European database focusing on the centres performing totally intracorporeal RARC. METHODS In the ERUS scientific working group database, 467 patients underwent totally intracorporeal RARC for bladder cancer between 2003 and 2014. Clinical and pathological data at the time of the latest follow-up was reviewed. Recurrence free survival (RFS), cancer specific survival (CSS) and overall survival (OS) were the outcomes of interest and evaluated using the Kaplan Meier estimator. Multivariable Cox regression analysis was performed to identify factors associated with outcomes of interest. RESULTS Mean age was 67 years, 80% were men. 384 (82%) patients were alive at the time of the analysis. Median follow-up was 17.9 months (range 1-130 months). 87 patients (19%) had undergone surgery 3 or more years' ago. Median follow-up of patients alive was 16 months. 31% patients had pathological non organ-confined disease. Positive surgical margins were present in 5%; median lymph node yield was 18 with 19% of patients having positive lymph nodes. The 3-year RFS, CSS and OS were 73%, 75% and 73% respectively. On multivariable analysis, non-organ confined disease was found to impact RFS, CSS and OS (HR 4.0, 4.3 and 4.2 respectively) and LN positive disease was associated with poorer RFS (HR 2.1). Histopathology stage pT0 was a positive prognostic indicator associated with better RFS, CSS and OS (HR 0.15, 0.16 and 0.74 respectively). CONCLUSIONS This is the largest reported multi-institutional cohort of totally intracorporeal RARC showing acceptable medium term survival outcomes comparable to open radical cystectomy series. The ERUS scientific working group database indicates that a totally intracorporeal approach is replicable.
![Research paper thumbnail of Corrigendum re: "Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group" [Eur Urol 2017;71:723-6]](https://attachments.academia-assets.com/72151217/thumbnails/1.jpg)
](European urology, Sep 27, 2017
In the original article, the name of author Mevlana Balbay was incorrectly spelt as Melvin D. Bal... more In the original article, the name of author Mevlana Balbay was incorrectly spelt as Melvin D. Balbay.
Purpose: Implementation of decision aids in medical decision making is still low, partly because ... more Purpose: Implementation of decision aids in medical decision making is still low, partly because of fear that involving patients could have a negative impact. This study focuses on the effect of increasing patient involvement, by means of a decision aid, on regret in the context of the treatment choice for prostate cancer. Method: Between 2008 and 2011, patients with localized prostate cancer were individually randomized to 1) usual care (n=77) and 2) usual care plus a discussion on risks and benefits of different treatment options by means of a decision aid (N=163). The treatments options were radical prostatectomy, external beam radiotherapy and brachytherapy. This was a multicenter trial (3 sites) with imbalanced randomization (1:2). The primary outcome measure was regret, which was assessed before, and 6 and 12 months after treatment with the regret scale of Brehaut(1), and with three newly developed regret scales focusing on process regret, option regret and outcome regret. Add...
The Journal of Urology, 1999
Tijdschrift voor Urologie, 2015
Health Expectations, 2015
Objective To develop and validate new regret scales and examine whether a decision aid affects di... more Objective To develop and validate new regret scales and examine whether a decision aid affects different aspects of regret in the treatment choice for prostate cancer.
Purpose: Implementation of decision aids in medical decision making is still low, partly because ... more Purpose: Implementation of decision aids in medical decision making is still low, partly because of fear that involving patients could have a negative impact. This study focuses on the effect of increasing patient involvement, by means of a decision aid, on regret in the context of the treatment choice for prostate cancer. Method: Between 2008 and 2011, patients with localized prostate cancer were individually randomized to 1) usual care (n=77) and 2) usual care plus a discussion on risks and benefits of different treatment options by means of a decision aid (N=163). The treatments options were radical prostatectomy, external beam radiotherapy and brachytherapy. This was a multicenter trial (3 sites) with imbalanced randomization (1:2). The primary outcome measure was regret, which was assessed before, and 6 and 12 months after treatment with the regret scale of Brehaut(1), and with three newly developed regret scales focusing on process regret, option regret and outcome regret. Add...
Tijdschrift voor Urologie, 2012
Bij 5 van de 36 onderzochte patiënten werden peroperatief tumorpositieve lymfeklieren gevonden, w... more Bij 5 van de 36 onderzochte patiënten werden peroperatief tumorpositieve lymfeklieren gevonden, waarna geen cystectomie volgde. Van deze 5 patiënten ontvingen er 3 wel een palliatieve brickerderivatie via een intracorporele procedure. Van de 31 resterende patiënten waren er 26 man en 5 vrouw. 20 patiënten kregen een brickerderivatie en 2 patiënten kregen een neoblaas via een intracorporele procedure. Een extracorporele procedure werd verricht bij 9 patiënten, waarvan 1 patiënt een brickerderivatie kreeg en 8 patiënten een neoblaas. De gemiddelde opnameduur na een intracorporele procedure was 16 dagen. De gemiddelde operatieduur was 420 minuten en het peri-operatieve bloedverlies was 231 ml. Bij 15 van de 22 patiënten (68%) traden postoperatief complicaties op, met een clavienclassificatie van I (n = 6), II (n = 5), III (n = 2) en IV (n = 1). De gemiddelde opnameduur na een extracorporele procedure was 17 dagen. De gemiddelde operatieduur was 388 minuten en het peri-operatieve bloedverlies was 1289 ml. Bij 6 van de 9 patiënten (67%) traden er postoperatief complicaties op met een clavienclassificatie van I (n = 3), II (n = 1) en IV (n = 2).
European Urology Supplements, 2007
Tijdschrift voor Urologie, 2013
European Urology Supplements, 2011
Tijdschrift voor Urologie, 2013
European Urology Supplements, 2014
Scientific Reports
Robot-Assisted Radical Prostatectomy (RARP) is one of the standard treatment options for prostate... more Robot-Assisted Radical Prostatectomy (RARP) is one of the standard treatment options for prostate cancer. However, controversy still exists on its added value. Based on a recent large-sample retrospective cluster study from the Netherlands showing significantly improved long-term urinary functioning after RARP compared to Laparoscopic RP (LRP), we evaluated the cost-effectiveness of RARP compared to LRP. A decision tree was constructed to measure the costs and effects from a Dutch societal perspective over a ~ 7 year time-horizon. The input was based on the aforementioned study, including patient-reported consumption of addition care and consumed care for ergonomic issues reported by surgeons. Intervention costs were calculated using a bottom-up costing analysis in 5 hospitals. Finally, a probabilistic-, one-way sensitivity- and scenario analyses were performed to show possible decision uncertainty. The intervention costs were €9964 for RARP and €7253 for LRP. Total trajectory costs...
ESMO Open
BACKGROUND Guidelines recommend neoadjuvant chemotherapy (NAC) for the treatment of nonmetastatic... more BACKGROUND Guidelines recommend neoadjuvant chemotherapy (NAC) for the treatment of nonmetastatic muscle-invasive bladder cancer (MIBC). NAC is, however, underutilized in practice because of its associated limited overall survival (OS) benefit and significant treatment-related toxicity. We hypothesized that the absence of circulating tumour cells (CTCs) identifies MIBC patients with such a favourable prognosis that NAC may be withheld. PATIENTS AND METHODS The CirGuidance study was an open-label, multicentre trial that included patients with clinical stage T2-T4aN0-N1M0 MIBC, scheduled for radical cystectomy. CTC-negative patients (no CTCs detectable using the CELLSEARCH system) underwent radical surgery without NAC; CTC-positive patients (≥1 detectable CTCs) were advised to receive NAC, followed by radical surgery. The primary endpoint was the 2-year OS in the CTC-negative group with a prespecified criterion for trial success of ≥75% (95% confidence interval (CI) ±5%). RESULTS A total of 273 patients were enrolled. Median age was 69 years; median follow-up was 36 months. The primary endpoint of 2-year OS in the CTC-negative group was 69.5% (N = 203; 95% CI 62.6%-75.5%). Two-year OS was 58.2% in the CTC-positive group (N = 70; 95% CI 45.5%-68.9%). CTC-positive patients had a higher rate of cancer-related mortality [hazard ratio (HR) 1.61, 95% CI 1.05-2.45, P = 0.03] and disease relapse (HR 1.87, 95% CI 1.28-2.73, P = 0.001) than CTC-negative patients. Explorative analyses suggested that CTC-positive patients who had received NAC (n = 22) survived longer than CTC-positive patients who had not (n = 48). CONCLUSION The absence of CTCs in MIBC patients was associated with improved cancer-related mortality and a lower risk of disease relapse after cystectomy; however, their absence alone does not justify to withhold NAC. Exploratory analyses suggested that CTC-positive MIBC patients might derive more benefit from NAC. TRIAL REGISTRATION Netherlands Trial Register NL3954; https://www.trialregister.nl/trial/3954.
European Urology Supplements, 2018
Development and internal-external validation of a multivariable prediction model for pre-operativ... more Development and internal-external validation of a multivariable prediction model for pre-operative assessment of positive lymph nodes during robot assisted prostatectomy in two Dutch high volume robotic centers
The Journal of Urology, 2016
European Urology Supplements, 2012
European Urology Supplements, 2015
ABSTRACT Collins J.1, Hosseini A.1, Nyberg T.1, Schumacher M.C.2, Wijburg C.3, Canda A.E.4, Balba... more ABSTRACT Collins J.1, Hosseini A.1, Nyberg T.1, Schumacher M.C.2, Wijburg C.3, Canda A.E.4, Balbay M.D.5, Decaestecker K.6, Schwentner C.7, Edeling S.8, Pokupić S.8, Mottrie A.9, Guru K.10, Wiklund N.P.1 1Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden, 2Hirslanden Klinik, Dept. of Urology, Aarau, Switzerland, 3Rijnstate Hospital, Dept. of Urology, Arnhem, The Netherlands, 4Yildirim Beyazit University, Dept. of Urology, Ankara, Turkey, 5Memorial Hospital, Dept. of Urology, Istanbul, Turkey, 6Zekenhuis University, Dept. of Urology, Ghent, Belgium, 7Tubingen University Hospital, Dept. of Urology, Tubingen, Germany, 8Da Vinci Zentrum, Dept. of Urology, Hanover, Germany, 9OLV Clinic, Dept. of Urology, Aalst, Belgium, 10Roswell Park Cancer Institute, Dept. of Urology, Buffalo, United States of America INTRODUCTION & OBJECTIVES: Radical cystectomy is associated with high complications rates irrespective of surgical approach. Worldwide most centers offering robot-assisted radical cystectomy (RARC) perform an extracorporeal urinary diversion, despite potential advantages of a completely minimally invasive technique. We describe complication outcomes after totally intracorporeal RARC from a multi-institutional database using a standardized and validated reporting methodology. MATERIAL & METHODS: Using the ERUS Scientific Working Group (ESWG) database, we identified 428 patients who underwent totally intracorporeal RARC with at least 90 days of follow-up. Complications were analyzed and graded according to the Clavien-Dindo Classification system and were further stratified by organ system. Secondary outcomes included identification of preoperative and intraoperative variables associated with the complications. Logistic regression models were used to define predictors of complications and readmission, using backward selection (p<0.05). RESULTS: Overall 64% (n=274) of patients experienced a complication within 90 days of their operation, 57% (n=242) and 23% (n=96) within 30 days and 30-90 days of surgery respectively. 36% of patients experienced low grade complications (Clavien grade 1-2) and 29% experienced high grade complications (Clavien grade ≥3). Thirty and 90 day mortality was 0.9% and 2.1%, respectively. Overall 30 day readmission rate was 27%. Infectious, gastrointestinal and genitourinary complications were most common (40%, 26%, and 21%, respectively). On multi-variable analysis of 0-90 day complications we found neobladder diversion and increasing age to be predictors of any grade complications. As a multi-institutional database, disparities in patient selection, operating standards and postoperative management are potential limitations of this study. CONCLUSIONS: Surgical morbidity after totally intracorporeal RARC is significant when reported using standardized reporting methods. The majority of complications are low grade. Accurate reporting of complications is necessary to clarify optimum approaches to radical cystectomy and to guide patient counseling.
The Journal of Urology, 2015
ABSTRACT INTRODUCTION AND OBJECTIVES Data on the oncological outcomes in patients undergoing robo... more ABSTRACT INTRODUCTION AND OBJECTIVES Data on the oncological outcomes in patients undergoing robot-assisted radical cystectomy (RARC) is limited. Globally extracorporeal urinary diversion following RARC remains the most common approach despite potential advantages of a completely minimally invasive approach. We report oncological outcomes and associated prognostic factors from a multi-institutional European database focusing on the centres performing totally intracorporeal RARC. METHODS In the ERUS scientific working group database, 467 patients underwent totally intracorporeal RARC for bladder cancer between 2003 and 2014. Clinical and pathological data at the time of the latest follow-up was reviewed. Recurrence free survival (RFS), cancer specific survival (CSS) and overall survival (OS) were the outcomes of interest and evaluated using the Kaplan Meier estimator. Multivariable Cox regression analysis was performed to identify factors associated with outcomes of interest. RESULTS Mean age was 67 years, 80% were men. 384 (82%) patients were alive at the time of the analysis. Median follow-up was 17.9 months (range 1-130 months). 87 patients (19%) had undergone surgery 3 or more years' ago. Median follow-up of patients alive was 16 months. 31% patients had pathological non organ-confined disease. Positive surgical margins were present in 5%; median lymph node yield was 18 with 19% of patients having positive lymph nodes. The 3-year RFS, CSS and OS were 73%, 75% and 73% respectively. On multivariable analysis, non-organ confined disease was found to impact RFS, CSS and OS (HR 4.0, 4.3 and 4.2 respectively) and LN positive disease was associated with poorer RFS (HR 2.1). Histopathology stage pT0 was a positive prognostic indicator associated with better RFS, CSS and OS (HR 0.15, 0.16 and 0.74 respectively). CONCLUSIONS This is the largest reported multi-institutional cohort of totally intracorporeal RARC showing acceptable medium term survival outcomes comparable to open radical cystectomy series. The ERUS scientific working group database indicates that a totally intracorporeal approach is replicable.
European urology, Sep 27, 2017
In the original article, the name of author Mevlana Balbay was incorrectly spelt as Melvin D. Bal... more In the original article, the name of author Mevlana Balbay was incorrectly spelt as Melvin D. Balbay.
Purpose: Implementation of decision aids in medical decision making is still low, partly because ... more Purpose: Implementation of decision aids in medical decision making is still low, partly because of fear that involving patients could have a negative impact. This study focuses on the effect of increasing patient involvement, by means of a decision aid, on regret in the context of the treatment choice for prostate cancer. Method: Between 2008 and 2011, patients with localized prostate cancer were individually randomized to 1) usual care (n=77) and 2) usual care plus a discussion on risks and benefits of different treatment options by means of a decision aid (N=163). The treatments options were radical prostatectomy, external beam radiotherapy and brachytherapy. This was a multicenter trial (3 sites) with imbalanced randomization (1:2). The primary outcome measure was regret, which was assessed before, and 6 and 12 months after treatment with the regret scale of Brehaut(1), and with three newly developed regret scales focusing on process regret, option regret and outcome regret. Add...
The Journal of Urology, 1999
Tijdschrift voor Urologie, 2015
Health Expectations, 2015
Objective To develop and validate new regret scales and examine whether a decision aid affects di... more Objective To develop and validate new regret scales and examine whether a decision aid affects different aspects of regret in the treatment choice for prostate cancer.
Purpose: Implementation of decision aids in medical decision making is still low, partly because ... more Purpose: Implementation of decision aids in medical decision making is still low, partly because of fear that involving patients could have a negative impact. This study focuses on the effect of increasing patient involvement, by means of a decision aid, on regret in the context of the treatment choice for prostate cancer. Method: Between 2008 and 2011, patients with localized prostate cancer were individually randomized to 1) usual care (n=77) and 2) usual care plus a discussion on risks and benefits of different treatment options by means of a decision aid (N=163). The treatments options were radical prostatectomy, external beam radiotherapy and brachytherapy. This was a multicenter trial (3 sites) with imbalanced randomization (1:2). The primary outcome measure was regret, which was assessed before, and 6 and 12 months after treatment with the regret scale of Brehaut(1), and with three newly developed regret scales focusing on process regret, option regret and outcome regret. Add...
Tijdschrift voor Urologie, 2012
Bij 5 van de 36 onderzochte patiënten werden peroperatief tumorpositieve lymfeklieren gevonden, w... more Bij 5 van de 36 onderzochte patiënten werden peroperatief tumorpositieve lymfeklieren gevonden, waarna geen cystectomie volgde. Van deze 5 patiënten ontvingen er 3 wel een palliatieve brickerderivatie via een intracorporele procedure. Van de 31 resterende patiënten waren er 26 man en 5 vrouw. 20 patiënten kregen een brickerderivatie en 2 patiënten kregen een neoblaas via een intracorporele procedure. Een extracorporele procedure werd verricht bij 9 patiënten, waarvan 1 patiënt een brickerderivatie kreeg en 8 patiënten een neoblaas. De gemiddelde opnameduur na een intracorporele procedure was 16 dagen. De gemiddelde operatieduur was 420 minuten en het peri-operatieve bloedverlies was 231 ml. Bij 15 van de 22 patiënten (68%) traden postoperatief complicaties op, met een clavienclassificatie van I (n = 6), II (n = 5), III (n = 2) en IV (n = 1). De gemiddelde opnameduur na een extracorporele procedure was 17 dagen. De gemiddelde operatieduur was 388 minuten en het peri-operatieve bloedverlies was 1289 ml. Bij 6 van de 9 patiënten (67%) traden er postoperatief complicaties op met een clavienclassificatie van I (n = 3), II (n = 1) en IV (n = 2).
European Urology Supplements, 2007
Tijdschrift voor Urologie, 2013
European Urology Supplements, 2011
Tijdschrift voor Urologie, 2013
European Urology Supplements, 2014